Compare LBTYA & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBTYA | RLAY |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Bermuda | United States |
| Employees | 6636 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | N/A | 2020 |
| Metric | LBTYA | RLAY |
|---|---|---|
| Price | $9.60 | $18.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $13.72 | ★ $19.50 |
| AVG Volume (30 Days) | 1.9M | ★ 3.5M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $15.41 | N/A |
| Revenue Next Year | $3.03 | $324.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $9.63 | $3.03 |
| 52 Week High | $13.52 | $20.79 |
| Indicator | LBTYA | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 25.06 | 50.31 |
| Support Level | N/A | $6.67 |
| Resistance Level | $11.50 | $20.79 |
| Average True Range (ATR) | 0.31 | 1.20 |
| MACD | -0.06 | -0.28 |
| Stochastic Oscillator | 1.01 | 1.99 |
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.